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Introduction
Drug-Induced Immune Haemolytic Anaemia (DIIHA) is a 
serious but uncommon complication, with an estimated incidence 
of 1 per million of the population1,2. Since their introduction 
in the early 1960s, cephalosporins have been well established 
causes of DIIHA, most commonly with the third generation 
cephalosporins, cefotetan and ceftriaxone.
Ceftazidime is often a first choice cephalosporin to treat 
pulmonary exacerbations due to Pseudomonas aeruginosa in 
people with cystic fibrosis (CF), but despite its frequent use 
DIIHA is rare, with only 4 (non-fatal) cases being reported 
between 1971 to 20142–4. For the first time, we present a case of 
DIIHA secondary to intravenous (IV) ceftazidime use in a person 
with CF.
Case report
A 23 year old female with CF (DF508/DF508) chronically 
infected with Pseudomonas aeruginosa presented with a 
2 week history of general malaise, increasing shortness of 
breath, a productive cough and a decline in FEV1. She began 
in-patient treatment for a pulmonary exacerbation and was 
commenced on a 14 day course of two antipseudomonal IV 
antibiotics (3g of Ceftazidime and 2 Mega-Units of Colistimeth-
ate Sodium three times a day) in line with accepted CF practice. 
Following initial improvement, on day 4 she developed new 
pyrexia, hypotension, tachycardia and jaundice, and had an 
increasing oxygen requirement without new chest X-ray 
changes.
Same day laboratory investigations confirmed severe haemo-
lytic anaemia - haemoglobin (Hb) had dropped from 127 g/L on 
admission to 45 g/L, with new hyper-bilirubinaemia (96 μmol/L, 
normal <21) and elevated Lactate Dehydrogenase (LDH) (1806 
U/L, normal <250). Haptoglobin, which binds free haemoglobin 
in haemolysis, was undetectable at <0.1g/L (normal 0.3 – 2.0). 
Subsequently, she developed a reticulocytosis (145 × 10^9/L, 
normal range 20–110). A direct Coomb’s test was strongly 
positive, confirming the presence of red blood cell directed 
antibodies. A peripheral blood smear was negative for schis-
tocytes and a clotting screen remained normal, thus excluding 
thrombotic microangiopathic processes, including disseminated 
intravascular coagulation and thrombotic thrombocytopenic 
purpura. Other investigations excluded other causes of 
haemolysis, including paroxysmal nocturnal haemoglobinuria, 
mycoplasma induced haemolysis and serum electrophoresis for 
lymphoproliferative disorders.
A putative diagnosis of Ceftazidime-induced DIIHA was made. 
Initial management included stopping the IV antibiotics and 
transfusing 2 units of packed red cells with parenteral steroid 
cover. Subsequently, oral steroids (Prednisolone 50mg/day) 
were commenced and continued until induction of remission. 
Once remission was achieved her steroids were to be tapered. As 
chronic haemolysis can induce folate deficiency, IV Folic Acid 
was also initiated. She improved significantly both clinically 
and biochemically, with her Hb recovering to 100 g/L within 
10 days.
Discussion
DIIHA is rare, under-recognised, and underdiagnosed, and data 
supporting it is poor. Often, only dramatic haemolysis leads to 
appropriate investigations2. DIIHA is commonly associated with 
the presence of drug-independent and dependent antibodies.
Drug-independent antibodies are true RBC autoantibodies, 
targeting RBC components and not the offending drug. It is 
postulated that such offending drugs affect the immune system 
to cause RBC autoantibody formulation and subsequent haemo-
lytic anaemia but the exact sensitization mechanism remains 
unknown2.
Drug-dependent antibodies result from immune sensitiza-
tion and generation of antibodies directed at epitopes on the 
drug and/or its metabolites, or a combination of drug and RBC 
membrane2,4. Specialized serological testing can confirm the 
diagnosis of DIIHA by demonstrating drug-dependent anti-
body induced haem-agglutination in vitro in the presence of 
the offending drug4. The identification of drug-dependent 
antibodies could be of clinical significance, as there is evidence 
suggesting that patients receiving a second course of the precipi-
tating drug or closely related drugs may develop a more severe, 
even fatal haemolytic anaemia due to cross-reactive antibodies1,2. 
Hence, patients with cephalosporin-induced haemolytic anaemia 
should never receive further cephalosporins.
Clinical manifestations of DIIHA lie on a spectrum ranging 
from mild to severe haemolysis, with life threatening complica-
tions including acute renal failure, disseminated intravascular 
coagulation and shock3. Early identification and instigation of 
appropriate treatment is essential. The keystone of management 
is the discontinuation of the precipitant drug. Glucocorticoids 
(1–1.5 mg/kg/day of prednisolone or equivalent in adults) are 
commonly employed in inducing remission via reduction in 
antibody production.
Our patient’s DIIHA occurred following the 10th dose of 
ceftazidime during her admission: this was her second course 
of this drug within two years. Rapid resolution of her haemo-
lytic anaemia on cessation of ceftazidime with a high index of 
suspicion pre-treatment made serological testing for ceftazidime 
dependent antibodies unnecessary.
This case highlights the need for CF clinicians and microbiol-
ogists to be aware of DIIHA and its potential manifestations in 
order to facilitate early recognition and prompt management.
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Consent
Written informed consent for the publication of this case report 
was obtained from the patient.
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All data underlying the results are available as part of the article 
and no additional source data are required.
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